Validation of pharmacodynamic assays to evaluate the clinical efficacy of an antisense compound (AEG 35156) targeted to the X-linked inhibitor of apoptosis protein XIAP

The inhibitor of apoptosis protein, XIAP, is frequently overexpressed in chemoresistant human tumours. An antisense oligonucleotide (AEG 35156/GEM 640) that targets XIAP has recently entered phase I trials in the UK. Method validation data are presented on three pharmacodynamic assays that will be u...

Celý popis

Uloženo v:
Podrobná bibliografie
Hlavní autoři: Cummings, J, Ward, T H, LaCasse, E, Lefebvre, C, St-Jean, M, Durkin, J, Ranson, M, Dive, C
Médium: Artigo
Jazyk:Inglês
Vydáno: Nature Publishing Group 2005
Témata:
Translational Therapeutics
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC2362094/
https://ncbi.nlm.nih.gov/pubmed/15685240
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6602363
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky